Literature DB >> 19897285

Short chain fatty acids exchange: Is the cirrhotic, dysfunctional liver still able to clear them?

Johanne G Bloemen1, Steven W M Olde Damink, Koen Venema, Wim A Buurman, Rajiv Jalan, Cornelis H C Dejong.   

Abstract

BACKGROUND & AIMS: Prebiotics are increasingly used to improve gut integrity. A presumed mechanism of their beneficial action is the synthesis of short chain fatty acids (SCFA: acetate, propionate and butyrate). High systemic concentrations of propionate and butyrate are toxic and can adversely affect the patient. In physiological situations the liver uses propionate and butyrate for energy metabolism. The aim of the present study was to investigate to which extent patients with liver cirrhosis are still able to metabolize portal derived SCFA in the liver.
METHODS: Twelve patients with liver cirrhosis and an intrahepatic portosystemic shunt (TIPSS) were studied. Blood was sampled from the femoral artery, portal and hepatic vein. Organ plasma flow was measured. Net release or uptake was calculated by multiplying the arteriovenous differences by plasma flow. SCFA plasma concentrations were measured using LC-MS.
RESULTS: Arterial concentrations were 124+/-12, 8+/-1 and 10+/-1micromol/l for acetate, propionate and butyrate, respectively. The gut produced 32.5+/-13.0, 4.8+/-1.3 and 6.2+/-2.1micromolkgbw(-1)h(-1) of acetate, propionate and butyrate, respectively. Assuming 70% portosystemic shunting, hepatic uptake of propionate and butyrate was 3.1+/-0.9 and 5.2+/-1.4micromolkgbw(-1)h(-1). Hepatic uptake of acetate was non significant (12.1+/-12.3micromolkgbw(-1)min(-1)). As a consequence of shunting, part of total acetate escaped from the splanchnic bed, which equalled 34.9+/-14.7micromolkgbw(-1)h(-1).
CONCLUSION: The liver of patients with stable cirrhosis is able to use butyrate and propionate, most likely preventing increased systemic concentrations. This suggests that prebiotics can be administered safely, but monitoring butyrate levels may be advisable in patients with diminished liver function. Copyright 2009 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19897285     DOI: 10.1016/j.clnu.2009.10.002

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  23 in total

Review 1.  The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism.

Authors:  Gijs den Besten; Karen van Eunen; Albert K Groen; Koen Venema; Dirk-Jan Reijngoud; Barbara M Bakker
Journal:  J Lipid Res       Date:  2013-07-02       Impact factor: 5.922

2.  Near-infrared fluorescence imaging of liver metastases in rats using indocyanine green.

Authors:  Joost R van der Vorst; Merlijn Hutteman; J Sven D Mieog; Karien E de Rooij; Eric L Kaijzel; Clemens W G M Löwik; Hein Putter; Peter J K Kuppen; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer
Journal:  J Surg Res       Date:  2011-02-02       Impact factor: 2.192

3.  Mathematical Modeling of the Gut-Bone Axis and Implications of Butyrate Treatment on Osteoimmunology.

Authors:  Mohammad Aminul Islam; Carley V Cook; Brenda J Smith; Ashlee N Ford Versypt
Journal:  Ind Eng Chem Res       Date:  2021-11-30       Impact factor: 3.720

Review 4.  Promises of microbiome-based therapies.

Authors:  Jasmohan S Bajaj; Siew C Ng; Bernd Schnabl
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

Review 5.  Short-chain fatty acids in control of body weight and insulin sensitivity.

Authors:  Emanuel E Canfora; Johan W Jocken; Ellen E Blaak
Journal:  Nat Rev Endocrinol       Date:  2015-08-11       Impact factor: 43.330

6.  Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites.

Authors:  Zidong Donna Fu; Julia Yue Cui
Journal:  Curr Pharmacol Rep       Date:  2017-03-03

Review 7.  Gut microbiota and host metabolism in liver cirrhosis.

Authors:  Makoto Usami; Makoto Miyoshi; Hayato Yamashita
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 8.  Gut microbial metabolites in obesity, NAFLD and T2DM.

Authors:  Emanuel E Canfora; Ruth C R Meex; Koen Venema; Ellen E Blaak
Journal:  Nat Rev Endocrinol       Date:  2019-05       Impact factor: 43.330

9.  Colorectal Oncogenesis and Inflammation in a Rat Model Based on Chronic Inflammation due to Cycling DSS Treatments.

Authors:  Asa Håkansson; Camilla Bränning; Göran Molin; Diya Adawi; Marie-Louise Hagslätt; Margareta Nyman; Bengt Jeppsson; Siv Ahrné
Journal:  Gastroenterol Res Pract       Date:  2011-10-05       Impact factor: 2.260

10.  Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor.

Authors:  Ruth X Wang; Morkos A Henen; J Scott Lee; Beat Vögeli; Sean P Colgan
Journal:  Gut Microbes       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.